ITGA2B and COVID-19: In COVID-19 patients, 16.5 [9.0–22.5] % of all platelet EVs were CD41+ and CD45+, providing evidence for aggregate formation between platelet- and leukocyte-derived EVs, whereas only 3.4 [1.6–8.5] % of CD41+CD45+ EVs were detected in healthy donors (Figure 4, left panel).